Z-Phe-DL-Ala-FMK

Category	SARS-CoV
CAS	197855-65-5
Description	Z-FA-FMK is an irreversible cysteine protease inhibitor, and it also inhibits caspases-2, -3, -6, and -7. Z-FA-FMK suppresses the degradation of fibrillar collagen by fibroblasts and osteoclasts, and reduces LPS-induced cytokine production via inhibition of NF-kappaB-dependent gene expression in macrophages.

Quotation Now

Product Information

Synonyms	Z-Phe-DL-Ala-fluoromethylketone; Zfa-fmk; benzyloxycarbonyl-Phe-Ala-fluormethylketone; benzyloxycarbonylphenylalanyl-alanine fluoromethyl ketone; Carbamic acid, N-((1S)-2-((3-fluoro-1-methyl-2-oxopropyl)amino)-2-oxo-1-(phenylmethyl)ethyl)-, phenylmethyl ester
IUPAC Name	benzyl N-[(2S)-1-[(4-fluoro-3-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]carbamate
Molecular Weight	386.42
Molecular Formula	C21H23FN2O4
Canonical SMILES	CC(C(=O)CF)NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
InChI	InChI=1S/C21H23FN2O4/c1-15(19(25)13-22)23-20(26)18(12-16-8-4-2-5-9-16)24-21(27)28-14-17-10-6-3-7-11-17/h2-11,15,18H,12-14H2,1H3,(H,23,26)(H,24,27)/t15?,18-/m0/s1
InChIKey	ASXVEBPEZMSPHB-PKHIMPSTSA-N
Boiling Point	630.5±55.0°C (Predicted)
Purity	≥95%
Density	1.2±0.06 g/cm3 (Predicted)
Solubility	Soluble in DMSO
Appearance	White solid
Application	Cysteine Proteinase Inhibitors
Storage	Store at -20°C
Complexity	517
Exact Mass	386.16418538
In Vitro	Z-FA-FMK ((1S)-Z-FA-FMK; 5-100 μM; 1 h; Jurkat cells) reduces levels of DEVDase activity and DNA fragmentation. Z-FA-FMK inhibits the externalization of phosphatidylserine induced by either MX2870-1 or MX781. Z-FA-FMK (100 μM; 1 h; Jurkat cells) inhibits Apoptosis. Z-FA-FMK inhibited the induction of DEVDase activity not only by the RRMs but also by other apoptotic insults, including etoposide-, ceramide-, and CD95/Fas receptor-mediated pathways Z-FA-FMK (0-100 μM; 1 h; Jurkat cells) inhibits Caspases 2, -3, -6, and -7 activity through repressed induction of DEVDase activity in Jurkat cells. Z-FA-FMK (0-20 μM; 48 h; HT1080 and mouse embryonic stem cells) blocks reoviral replication and cures cells of a persistent infection with reovirus in vitro. Z-FA-FMK (20 μM; 48 h; HT1080 cells) induces defects in reoviral maturation.
In Vivo	Z-FA-FMK (1 mg/kg; intratumor injection; every 2 d, for 27 d; SCID mice with HT1080 xenograft) blocks reovirus infection in vivo. Z-FA-FMK (8 mg/kg; i.v.; every 2 d, once; male BALB/c mice) markedly lessens the degree of impairment seen in D-GalN/TNF-α-induced kidney injury.
PSA	84.50000
Target	Cathepsin B cathepsin L Caspase-2 Caspase-3 Caspase-6 Caspase-7
XLogP3-AA	3.3